Suppr超能文献

比较致心律失常性右室心肌病/发育不良患者与扩张型心肌病患者和健康对照者的候选分子在心肌中的表达谱。

Myocardial expression profiles of candidate molecules in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia compared to those with dilated cardiomyopathy and healthy controls.

机构信息

Department of Cardiology, University Heart Center Zurich, Zurich, Switzerland.

Department of Cardiology, University Heart Center Zurich, Zurich, Switzerland; Department of Cardiology, University Hospital Bern, Bern, Switzerland.

出版信息

Heart Rhythm. 2016 Mar;13(3):731-41. doi: 10.1016/j.hrthm.2015.11.010. Epub 2015 Nov 10.

Abstract

BACKGROUND

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is mainly an autosomal dominant disease characterized by fibrofatty infiltration of the right ventricle, leading to ventricular arrhythmias. Mutations in desmosomal proteins can be identified in about half of the patients. The pathogenic mechanisms leading to disease expression remain unclear.

OBJECTIVE

The purpose of this study was to investigate myocardial expression profiles of candidate molecules involved in the pathogenesis of ARVC/D.

METHODS

Myocardial messenger RNA (mRNA) expression of 62 junctional molecules, 5 cardiac ion channel molecules, 8 structural molecules, 4 apoptotic molecules, and 6 adipogenic molecules was studied. The averaged expression of candidate mRNAs was compared between ARVC/D samples (n = 10), nonfamilial dilated cardiomyopathy (DCM) samples (n = 10), and healthy control samples (n = 8). Immunohistochemistry and quantitative protein expression analysis were performed. Genetic analysis using next generation sequencing was performed in all patients with ARVC/D.

RESULTS

Following mRNA levels were significantly increased in patients with ARVC/D compared to those with DCM and healthy controls: phospholamban (P ≤ .001 vs DCM; P ≤ .001 vs controls), healthy tumor protein 53 apoptosis effector (P = .001 vs DCM; P ≤ .001 vs controls), and carnitine palmitoyltransferase 1β (P ≤ .001 vs DCM; P = 0.008 vs controls). Plakophillin-2 (PKP-2) mRNA was downregulated in patients with ARVC/D with PKP-2 mutations compared with patients with ARVC/D without PKP-2 mutations (P = .04). Immunohistochemistry revealed significantly increased protein expression of phospholamban, tumor protein 53 apoptosis effector, and carnitine palmitoyltransferase 1β in patients with ARVC/D and decreased PKP-2 expression in patients with ARVC/D carrying a PKP-2 mutation.

CONCLUSION

Changes in the expression profiles of sarcolemmal calcium channel regulation, apoptosis, and adipogenesis suggest that these molecular pathways may play a critical role in the pathogenesis of ARVC/D, independent of the underlying genetic mutations.

摘要

背景

致心律失常性右室心肌病/发育不良(ARVC/D)主要是一种常染色体显性疾病,其特征是右心室纤维脂肪浸润,导致室性心律失常。约半数患者可识别桥粒蛋白突变。导致疾病表达的发病机制仍不清楚。

目的

本研究旨在探讨参与 ARVC/D 发病机制的候选分子的心肌表达谱。

方法

研究了 62 个连接分子、5 个心脏离子通道分子、8 个结构分子、4 个凋亡分子和 6 个脂肪生成分子的心肌信使 RNA(mRNA)表达。将 ARVC/D 样本(n=10)、非家族性扩张型心肌病(DCM)样本(n=10)和健康对照样本(n=8)的候选 mRNA 平均表达进行比较。进行免疫组织化学和定量蛋白表达分析。对所有 ARVC/D 患者进行下一代测序的遗传分析。

结果

与 DCM 和健康对照组相比,ARVC/D 患者的以下 mRNA 水平显著升高:肌浆网磷蛋白(PLN;P ≤.001 与 DCM;P ≤.001 与对照组)、肿瘤抑制蛋白 53 凋亡效应物(TP53AE;P =.001 与 DCM;P ≤.001 与对照组)和肉毒碱棕榈酰基转移酶 1β(CPT1β;P ≤.001 与 DCM;P = 0.008 与对照组)。与 ARVC/D 无 PKP-2 突变患者相比,ARVC/D 患者中 PKP-2 基因突变患者的 PKP-2 mRNA 下调(P =.04)。免疫组织化学显示 ARVC/D 患者 PLN、TP53AE 和 CPT1β 的蛋白表达显著增加,而携带 PKP-2 突变的 ARVC/D 患者的 PKP-2 表达减少。

结论

肌浆网钙通道调节、细胞凋亡和脂肪生成表达谱的变化表明,这些分子途径可能在 ARVC/D 的发病机制中发挥关键作用,而与潜在的基因突变无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验